Evotec, a Germany-based biotech company, has collaborated with The Global Antibiotic Research and Development Partnership (GARDP) to discover antibiotics intended for the treatment of drug-resistant bacterial infections, it was reported yesterday.
Both parties say that they will strive to address the increasing threat of antimicrobial resistance.
The alliance will integrate The GARDP's clinical expertise and Evotec's drug discovery platform, medicinal chemistry and pharmacology expertise and its range of bacterial pathogens. The collaboration will concentrate on fast tracking the development of antibiotic treatments for hard-to-treat bacterial infections by creating a platform that will cover the length of the drug development value chain. The collaborators will also work on developing a joint pipeline and also claim to ensure that any discovered antibiotics are priced sensibly and are globally available to all patients who require them.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients